Juan Gómez1, Guillermo M Albaiceta2, Elías Cuesta-Llavona3, Marta García-Clemente4, Carlos López-Larrea5, Laura Amado-Rodríguez2, Inés López-Alonso6, Santiago Melón7, Marta E Alvarez-Argüelles7, Helena Gil-Peña3, José R Vidal-Castiñeira8, Viviana Corte-Iglesias8, María L Saiz8, Victoria Alvarez3, Eliecer Coto9. 1. Genética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado deAsturias, ISPA, Oviedo, Spain; Red de Investigación Renal (REDINREN), Madrid, Spain. 2. Unidad de Cuidados Intensivos Cardiológicos, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado deAsturias, ISPA, Oviedo, Spain; Universidad de Oviedo, Oviedo, Spain; CIBER-Enfermedades Respiratorias. Instituto de Salud Carlos III, Madrid, Spain; Instituto Universitario de Oncología del Principado de Asturias. Oviedo, Spain. 3. Genética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado deAsturias, ISPA, Oviedo, Spain. 4. Neumología, Hospital Universitario Central Asturias, Oviedo, Spain. 5. Inmunología, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado deAsturias, ISPA, Oviedo, Spain; Universidad de Oviedo, Oviedo, Spain; Red de Investigación Renal (REDINREN), Madrid, Spain. 6. Instituto de Investigación Sanitaria del Principado deAsturias, ISPA, Oviedo, Spain; CIBER-Enfermedades Respiratorias. Instituto de Salud Carlos III, Madrid, Spain. 7. Microbiología, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado deAsturias, ISPA, Oviedo, Spain. 8. Instituto de Investigación Sanitaria del Principado deAsturias, ISPA, Oviedo, Spain. 9. Genética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado deAsturias, ISPA, Oviedo, Spain; Universidad de Oviedo, Oviedo, Spain; Red de Investigación Renal (REDINREN), Madrid, Spain. Electronic address: eliecer.coto@sespa.es.
Abstract
BACKGROUND AND AIMS: The interferon-induced transmembrane proteins play an important antiviral role by preventing viruses from traversing the cellular lipid bilayer. IFITM3 gene variants have been associated with the clinical response to influenza and other viruses. Our aim was to determine whether the IFITM3 rs12252 polymorphism was associated with the risk of developing severe symptoms of COVID-19 in our population. METHODS: A total of 288 COVID-19 patients who required hospitalization (81 in the intensive care unit) and 440 age matched controls were genotyped with a Taqman assay. Linear regression models were used to compare allele and genotype frequencies between the groups, correcting for age and sex. RESULTS: Carriers of the minor allele frequency (rs12252 C) were significantly more frequent in the patients compared to controls after correcting by age and sex (p = 0.01, OR = 2.02, 95%CI = 1.19-3.42). This genotype was non-significantly more common among patients who required ICU. CONCLUSIONS: The IFITM3 rs12252 C allele was a risk factor for COVID-19 hospitalization in our Caucasian population. The extent of the association was lower than the reported among Chinese, a population with a much higher frequency of the risk allele.
BACKGROUND AND AIMS: The interferon-induced transmembrane proteins play an important antiviral role by preventing viruses from traversing the cellular lipid bilayer. IFITM3 gene variants have been associated with the clinical response to influenza and other viruses. Our aim was to determine whether the IFITM3rs12252 polymorphism was associated with the risk of developing severe symptoms of COVID-19 in our population. METHODS: A total of 288 COVID-19patients who required hospitalization (81 in the intensive care unit) and 440 age matched controls were genotyped with a Taqman assay. Linear regression models were used to compare allele and genotype frequencies between the groups, correcting for age and sex. RESULTS: Carriers of the minor allele frequency (rs12252 C) were significantly more frequent in the patients compared to controls after correcting by age and sex (p = 0.01, OR = 2.02, 95%CI = 1.19-3.42). This genotype was non-significantly more common among patients who required ICU. CONCLUSIONS: The IFITM3rs12252 C allele was a risk factor for COVID-19 hospitalization in our Caucasian population. The extent of the association was lower than the reported among Chinese, a population with a much higher frequency of the risk allele.
Authors: Monique R O Trugilho; Isaclaudia G Azevedo-Quintanilha; João S M Gesto; Emilly Caroline S Moraes; Samuel C Mandacaru; Mariana M Campos; Douglas M Oliveira; Suelen S G Dias; Viviane A Bastos; Marlon D M Santos; Paulo C Carvalho; Richard H Valente; Eugenio D Hottz; Fernando A Bozza; Thiago Moreno L Souza; Jonas Perales; Patrícia T Bozza Journal: Cell Death Discov Date: 2022-07-16
Authors: João Locke Ferreira de Araújo; Diego Menezes; Renato Santana de Aguiar; Renan Pedra de Souza Journal: Front Genet Date: 2022-04-01 Impact factor: 4.599
Authors: Helena Winstone; Maria Jose Lista; Alisha C Reid; Clement Bouton; Suzanne Pickering; Rui Pedro Galao; Claire Kerridge; Katie J Doores; Chad M Swanson; Stuart J D Neil Journal: J Virol Date: 2021-04-12 Impact factor: 5.103
Authors: Fanny Pojero; Giuseppina Candore; Calogero Caruso; Danilo Di Bona; David A Groneberg; Mattia E Ligotti; Giulia Accardi; Anna Aiello Journal: Int J Mol Sci Date: 2021-03-05 Impact factor: 5.923